The timed run also reduced total review time from almost 26 hours for Enveda’s four reviewers to just under three hours, ...
Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76 ...
Investigational oral therapy targeting rhodopsin protein misfolding is currently undergoing Phase 1/2 clinical evaluation for ...
Accord now holds two pegfilgrastim biosimilars in one market, its in-house Ennumo and the acquired Udenyca. Owning both the ...
For any company with a Japan P&L, that decision collapses into eight numbers. Each is set out below in the same four lines: ...
TJ Biopharma Doses First Patient in Phase I Trial of CLDN6 × 4-1BB Bispecific Antibody for Advanced Solid Tumours ...
MEPSGEN US, Inc., a global innovator in drug delivery system platforms, announced the launch of NanoCalibur® Mini, an ...
NMPA accepts new indication application following Phase II MIZAR-003 results demonstrating a 57% reduction in the risk of ...
Enhertu ® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment ...
Partnership targets ALK7 in adipose tissue to develop a differentiated obesity treatment aimed at reducing visceral fat while preserving lean muscle mass, potentially complementing existing ...
Strategic collaboration aims to accelerate biomarker development, streamline global clinical trials and expand precision medicine capabilities, with a focus on integrating China into multinational ...
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results